Abstract
Background and Objectives
Eltrombopag is a thrombopoietic growth factor that is approved for the treatment of thrombocytopenia in chronic hepatitis C virus (HCV) patients. We aimed to describe eltrombopag population pharmacokinetics in hepatitis C patients. Bayesian statistical approach will be applied to screen for patients’ characteristics associated with eltrombopag pharmacokinetic parameters.
Methods
A population pharmacokinetic analysis was conducted using WinBUGS version 1.4.3. Data from 483 individuals with chronic HCV infection were analyzed. This analysis is a secondary analysis of two clinical studies (ENABLE1 and ENABLE2) sponsored by GlaxoSmithKline. Several patients’ characteristics were examined as possible covariates of the population pharmacokinetic model. Prior information from previous studies was incorporated in the bayesian model as prior distribution to estimate pharmacokinetic parameters.
Results
A two-compartment pharmacokinetic model with first-order absorption with exponential error model best fit the data. We identified East Asian race and total bilirubin level as predictors of eltrombopag clearance. Typical value for distributional clearance was 0.762 L/h (95% Bayesian credible set, 0.703–0.826), for volume of distribution of the central and peripheral compartments were 12 L (10.9–13.4) and 10.9 L (10.4–11.5), and for absorption lag time was 0.947 h (0.918–0.977). Assuming an average total bilirubin of 21.7 µmol/L, the typical elimination clearance value for an East Asian patient was 0.14 L/h and for other races was 0.20 L/h.
Conclusions
Eltrombopag pharmacokinetic behavior was described using population bayesian approach. This model can be applied to optimize eltrombopag dosing in order to reduce the incidence of thrombocytopenia in HCV-infected patient receiving interferon-based therapy.
Similar content being viewed by others
References
Abad S, Vega A, Hernandez E, Merida E, de Sequera P, Albalate M, et al. Universal sustained viral response to the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4. Am J Nephrol. 2017;45(3):267–72. https://doi.org/10.1159/000454819.
Center for Disease Control and Prevention. Surveillance for viral hepatitis—United States, 2015. United States: CDC; 2015.
Shiffman ML. Chronic hepatitis C virus: advances in treatment, promise for the future. New York: Springer; 2011.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.
Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23(8):1055–65. https://doi.org/10.1111/j.1365-2036.2006.02889.x.
Giannini EG, Savarino V. Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye. J Viral Hepat. 2011;18(1):8–10. https://doi.org/10.1111/j.1365-2893.2010.01368.x.
Keohane EM, Walenga JM, Smith LJ. Rodak’s hematology: clinical principles and applications. Philadelphia: Elsevier Saunders; 2015.
Aspinall R, Pockros P. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20(9):917–29.
Bordin G, Ballare M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol. 1995;13(Suppl 13):S39–43.
McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Bailliere’s Best Pract Res Clin Gastroenterol. 2000;14(6):1009–31. https://doi.org/10.1053/bega.2000.0144.
Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001;113(3):590–5.
Skidmore-Roth L. Mosby’s 2014 nursing drug reference. 27th ed. Mosby: Skidmore Nursing Drug Reference; 2014.
Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132(1):103–12. https://doi.org/10.1053/j.gastro.2006.11.011.
Hodgson BB, Kizior RJ. Saunders nursing drug handbook 2014—E-Book. Amsterdam: Elsevier Health Sciences; 2013.
Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69(5):567–76.
Deng Y, Madatian A, Wire MB, Bowen C, Park J, Williams D, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011. https://doi.org/10.1124/dmd.111.040170.
Lexi-Comp Inc., American Pharmaceutical Association. Drug information handbook. < 1996/97 > -2008/2009: Lexi-Comp’s clinical reference library. North American ed. Hudson, Ohio Washington, DC: Lexi-Comp, American Pharmaceutical Association; 2009. p. 2117.
Farrell C, Hayes SC, Wire M, Zhang J. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease. Br J Clin Pharmacol. 2014;77(3):532–44.
Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book: a practical introduction to Bayesian analysis. Boca Raton: CRC Press; 2012.
Wu K, Thapar M, Farrell C, Hayes S, Guo H, Hou M, et al. Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in chinese patients with chronic primary immune thrombocytopenia. Clin Ther. 2015;37(7):1382–95. https://doi.org/10.1016/j.clinthera.2015.03.024.
Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51(6):842–56.
Gibiansky E, Mudd Jr P, Kamel Y, Kamel YM, editors. Population pharmacokinetics of eltrombopag in patients with cancer and healthy subjects. AAPS Annual Meeting; 2009.
Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Stat Methodol). 2002;64(4):583–639.
Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J. 2012;14(1):119–32.
Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. New York: Wiley; 2013.
Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ; 2001.
D’Argenio D. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Berlin: Springer; 2006.
Dunson DB. Commentary: practical advantages of Bayesian analysis of epidemiologic data. Am J Epidemiol. 2001;153(12):1222–6.
Saleh MI. A Bayesian approach for population pharmacokinetic modeling of pegylated interferon α-2a in hepatitis C patients. Clin Pharmacokinet. 2017;56(11):1369–79.
Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, et al. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011. https://doi.org/10.1124/dmd.110.037960.
Hayes S, Mudd PN, Ouellet D, Johnson BM, Williams D, Gibiansky E. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol. 2013;71(6):1507–20.
Zhang J, Thapar M, Farrell C, Wire MB. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection. Pharm Res. 2015;32(6):2015–28.
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Boca Raton: Taylor & Francis; 1982.
Lee P, Aizawa H, Gan L, Prakash C, Zhong D. Handbook of metabolic pathways of xenobiotics. New York: Wiley; 2014.
Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015;42(10):1030–5.
Bonate PL. Pharmacokinetic–pharmacodynamic modeling and simulation. Berlin: Springer; 2011.
Bauer LA. Applied clinical pharmacokinetics 3/E. New York: McGraw-Hill Education; 2014.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding has been received for the conduct of this study and/or preparation of this manuscript.
Conflicts of interest
The authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Saleh, M.I., Melhim, S.B., Al-Ramadhani, H.M. et al. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. Eur J Drug Metab Pharmacokinet 44, 31–42 (2019). https://doi.org/10.1007/s13318-018-0490-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-018-0490-x